Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

258.68 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 258.68
Bid (Size) 228.88 (3)
Ask (Size) 258.01 (1)
Prev. Close 258.68
Today's Range 258.68 - 258.68
52wk Range 181.00 - 323.62
Shares Outstanding 68,873,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What 8 Analyst Ratings Have To Say About Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
 
Via Benzinga

Performance

YTD
-6.17%
-6.17%
1 Month
+12.07%
+12.07%
3 Month
+35.98%
+35.98%
6 Month
+4.44%
+4.44%
1 Year
-9.76%
-9.76%

More News

Read More
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Recap: Insulet Q2 Earnings
Via Benzinga
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)
From Insulet Corporation
Via Business Wire
5 Analysts Have This to Say About Insulet
Via Benzinga
4 Analysts Have This to Say About Insulet
Via Benzinga
Expert Ratings for Insulet
Via Benzinga
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System
From Insulet Corporation
Via Business Wire
The Healthcare Companies Fighting the World’s Biggest Killers
Via FinancialNewsMedia
Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Via Benzinga
7 Stocks to Buy That Could Make You a Millionaire
Via InvestorPlace
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
Via Benzinga
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
From Insulet Corporation
Via Business Wire
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
Via Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
Via Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
Via Investor's Business Daily
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
Via InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
Via InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.